ASCO 2019 | Novel agents and precision medicine in prostate cancer care

Daniel Petrylak • 2 Jun 2019

ASCO 2019

Daniel Petrylak, MD, of the Yale School of Medicine, New Haven, CT, discusses the integration of novel agents and precision medicine into prostate cancer care at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.

0:50

PSMA ADC for prostate cancer

Daniel Petrylak • 2 Jun 2019

1:37

ARCHES: OS in mHSPC who recieved prior ADT and reached low PSA further treated with enzalutamide

Daniel Petrylak • 11 Sep 2022

0:42

Targeted therapies in metastatic urothelial carcinoma

Daniel Petrylak • 17 Feb 2022

Daniel Petrylak: GU 2020 prostate picks

Daniel Petrylak • 15 Feb 2020

Related Videos

2:58

Challenges of nmCRPC management: to treat or not?

Robert Jones • 18 Jan 2019

3:23

Improving the current chemotherapy standard: a role for DNA methyltransferase inhibitors

Simon Crabb • 16 Nov 2018

4:24

Cabozantinib plus docetaxel and prednisone in mCRPC

Munjid Al Harthy • 18 Feb 2019

2:04

How to involve patients in clinical decision making

Joe O'Sullivan • 29 Nov 2018

ASCO 2019 | Novel agents and precision medicine in prostate cancer care

More from Daniel Petrylak

Related Videos

Sign-up for our Newsletter!